99 Wall Street, Suite 232, New York, NY 10005

Need Help? Call : (800) 991-3756

Class Action Cases

A class action has been filed on behalf of NKTR Investors. Click "Join this Class Action" above.

Attorneys

Nektar Therapeutics

Join Class Action »

Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019 (the “Class Period”). The lawsuit seeks to recover damages for Nektar investors under the federal securities laws.

If you bought Nektar Therapeutics securities between February 15, 2019 through August 8, 2019, and would like to join the action, please click “Join This Class Action,” above.

Press Release

SHAREHOLDER ALERT: Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Nektar Therapeutics- NKTR

New York, N.Y., September 10, 2019. Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Nektar Therapeutics (NKTR) between February 15, 2019 and August 8, 2019, inclusive (the “Class Period”).

To join the NKTR class action, go to http://zhanginvestorlaw.com/cases/nektar-therapeutics/ call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) that the Company did not comply with current good manufacturing practices; (2) that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully; (3) that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study; (4) that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit; and (5) as a result, Nektar’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 18, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://zhanginvestorlaw.com/cases/nektar-therapeutics/ or to discuss your rights or interests regarding this class action, please contact Sophie Zhang, Esq. of Zhang Investor Law toll free at 800-991-3756 or via e-mail at info@zhanginvestorlaw.com.

Zhang Investor Law represents investors worldwide.